Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: Results of a placebo-controlled trial
Authors:
- the Ramipril Study GroupTGthe Ramipril Study Group
- 1 August 1995
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 9 (4) , 589-594
Abstract
The assessment of quality of life (QoL) has become recognized as an important tool for evaluating heart failure therapy. The angiotensin-converting enzyme inhibitor ramipril (mean dose 8 mg) was evaluated in 223 patients with moderate chronic congestive heart failure at 24 centers in 4 Nordic countries following a randomized, double-blind, placebo-controlled, parallel group design. The follow-up period was 12 weeks. QoL was evaluated using a questionnaire with 47 items, including the disease-specific Severe Heart Failure Questionnaire, the Sleep Dysfunction Scale, and the Psychological General Well-Being Index. In both treatment groups the total score increased from baseline to 12 weeks for both the Severe Heart Failure Questionnaire and for the Psychological Well-Being Index, reflecting relief of symptoms and improved well-being. However, no significant differences between the placebo and ramipril groups could be detected. Only a trend toward improvement in sleep on ramipril compared with placebo therapy was observed. In conclusion, in this placebo-controlled trial no significant effects of 12-week ramipril treatment of QoL could be demonstrated in patients with moderate congestive heart failure.Keywords
This publication has 22 references indexed in Scilit:
- Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial.Heart, 1992
- A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart FailureNew England Journal of Medicine, 1991
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- The Effects of ACE Inhibitors on Exercise Capacity in the Treatment of Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1990
- Short- and long-acting angiotensin-converting enzyme inhibitors: A randomized trial of lisinopril versus captopril in the treatment of congestive heart failureJACC, 1989
- Comparison of enalapril versus digoxin for congestive heart failureThe American Journal of Cardiology, 1989
- Comparative Effects of Therapy With Captopril and Digoxin in Patients With Mild to Moderate Heart FailureJAMA, 1988
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Placebo-Controlled Study of Lisinopril in Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1987
- A placebo-controlled trial of captopril in refractory chronic congestive heart failureJACC, 1983